EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Effects of Silybum marianum, Pueraria lobate, combined with Salvia miltiorrhiza tablets on non-alcoholic fatty liver disease in adults: A triple-blind, randomized, placebo-controlled clinical trial

Bang-Yan Li, Yue Xi, Yu-Ping Liu, Di Wang, Cheng Wang, Chao-Gang Chen, Xiao-Hong Fang, Zhong-Xia Li, Yu-Ming Chen

Clinical Nutrition ESPEN · 2024-10 · 63 · 2-12

DOI: 10.1016/j.clnesp.2024.06.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition ESPEN, 2024-10. Verfasst von Bang-Yan Li und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China. Electronic address: liby35@mail2.sysu.edu.cn. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Pueraria, Salvia miltiorrhiza, Silybum marianum. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND & AIMS: Several medicinal plant extracts have demonstrated hepatoprotective effects. However, data are scarce regarding their combined effects on non-alcoholic fatty liver disease (NAFLD). This study aimed to investigate the effects of tablets containing Silybum marianum, Pueraria lobata, and Salvia miltiorrhiza (SPS) on NAFLD progression in Chinese adults. METHODS: In this randomized, triple-blind, placebo-controlled clinical trial, 121 NAFLD patients (60 female and 61 male), diagnosed via magnetic resonance imaging (MRI) and aged 18-65 years, were enrolled. Participants were randomly allocated to receive SPS tablets (n = 60; three tablets per dose, twice daily) or placebo (n = 61) for 24 weeks. Each SPS tablet contained approximately 23.0 mg of silybin, 11.4 mg of puerarin, and 10.9 mg of salvianolic acid. There were no differences in appearance, taste and odour between the SPS tablets and placebo manufactured by BYHEALTH Co., LTD (Guangzhou, China). The primary endpoints were changes in the liver fat content (LFC) and steatosis grade from baseline to 24 weeks. Secondary outcomes included changes in biomarkers/scores of liver fibrosis and steatosis, oxidative stress, inflammatory cytokines, alcohol metabolism, and glucose metabolism. RESULTS: A total of 112 participants completed the research. The intention-to-treat results showed a trend toward reduction in both absolute LFC (-0.52%) and percentage of LFC (-4.57%) in the SPS group compared to the placebo group after 24 weeks, but these changes didn't reach statistical significance (p > 0.05). The SPS intervention (vs. placebo) significantly decreased hypersensitive C-reactive protein level (-6.76%) and increased aldehyde dehydrogenase activity (+18.1%) at 24 weeks post-intervention (all p < 0.05). Per-protocol analysis further supported these effects. This trial is registered at Clinical Trials.gov (NCT05076058). CONCLUSION: SPS supplementation may have potential benefits in improving NAFLD, but further larger-scale trials are necessary to confirm these findings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseasePuerariaSalvia miltiorrhizaSilybum marianumTabletsHumansFemaleMaleAdultMiddle AgedYoung AdultPlant ExtractsDrugs, Chinese HerbalAgedAdolescentTreatment Outcome

Stichwörter der Autor:innen

InflammationNonalcoholic fatty liver diseasePuerarinSalvianolic acidSilybin

Substanzen

TabletsPlant ExtractsDrugs, Chinese Herbal

Autor:innen und Institutionen

  • Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China. Electronic address: liby35@mail2.sysu.edu.cn.
  • Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China. Electronic address: xiyue5@mail2.sysu.edu.cn.
  • Department of Epidemiology, School of Public Health, Sun Yat-Sen University, Guangzhou, China; Sichuan Center for Disease Control and Prevention, Chengdu, China. Electronic address: liuyuping9999@163.com.
  • BYHEALTH Institute of Nutrition & Health, Guangzhou 510663, China. Electronic address: wangd7@by-health.com.
  • Clinical Nutrition Department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China. Electronic address: wangcheng@mail.sysu.edu.cn.
  • Clinical Nutrition Department of Sun Yat-sen Memorial Hospital, Sun Yat-sen University, China. Electronic address: chenchg@mail.sysu.edu.cn.

Zitieren

APA

Li, B. Y., Xi, Y., Liu, Y. P., Wang, D., Wang, C., Chen, C. G., Fang, X. H., Li, Z. X., & Chen, Y. M. (2024). Effects of Silybum marianum, Pueraria lobate, combined with Salvia miltiorrhiza tablets on non-alcoholic fatty liver disease in adults: A triple-blind, randomized, placebo-controlled clinical trial. Clinical Nutrition ESPEN, 63, 2-12. https://doi.org/10.1016/j.clnesp.2024.06.003

Vancouver

Li BY, Xi Y, Liu YP, Wang D, Wang C, Chen CG, et al. Effects of Silybum marianum, Pueraria lobate, combined with Salvia miltiorrhiza tablets on non-alcoholic fatty liver disease in adults: A triple-blind, randomized, placebo-controlled clinical trial. Clinical Nutrition ESPEN. 2024;63:2-12. doi:10.1016/j.clnesp.2024.06.003

BibTeX
@article{Li2024,
  author = {Li, Bang-Yan and Xi, Yue and Liu, Yu-Ping and Wang, Di and Wang, Cheng and Chen, Chao-Gang and Fang, Xiao-Hong and Li, Zhong-Xia and Chen, Yu-Ming},
  title = {Effects of Silybum marianum, Pueraria lobate, combined with Salvia miltiorrhiza tablets on non-alcoholic fatty liver disease in adults: A triple-blind, randomized, placebo-controlled clinical trial},
  journal = {Clinical Nutrition ESPEN},
  year = {2024},
  volume = {63},
  pages = {2--12},
  doi = {10.1016/j.clnesp.2024.06.003}
}
Kostenlos starten →